Literature DB >> 23981606

Tamoxifen-resistant breast cancer cells possess cancer stem-like cell properties.

Hui Liu1, Heng-wei Zhang, Xian-fu Sun, Xu-hui Guo, Ya-ning He, Shu-de Cui, Qing-xia Fan.   

Abstract

BACKGROUND: Cancer stem cells (CSCs) are the cause of cancer recurrence because they are resistant to conventional therapy and contribute to cancer growth and metastasis. Endocrinotherapy is the most common breast cancer therapy and acquired tamoxifen (TAM) resistance is the main reason for endocrinotherapy failure during such therapy. Although acquired resistance to endocrine treatment has been extensively studied, the underlying mechanisms are unclear. We hypothesized that breast CSCs played an important role in TAM-induced resistance during breast cancer therapy. Therefore, we investigated the biological characteristics of TAM-resistant (TAM-R) breast cancer cells.
METHODS: Mammosphere formation and tumorigenicity of wild-type (WT) and TAM-R MCF7 cells were tested by a mammosphere assay and mouse tumor xenografts respectively. Stem-cell markers (SOX-2, OCT-4, and CD133) and epithelial-mesenchymal transition (EMT) markers were tested by quantitative real-time (qRT)-PCR. Morphological observation was performed to characterize EMT.
RESULTS: After induction of TAM resistance, TAM-R MCF7 cells exhibited increased proliferation in the presence of TAM compared to that of WT MCF7 cells (P < 0.05), indicating enhanced TAM resistance of TAM-R MCF7 cells compared to that of WT MCF7 cells. TAM-R MCF7 cells showed enhanced mammosphere formation and tumorigenicity in nude mice compared to that of WT MCF7 cells (P < 0.01), demonstrating the elevated CSC properties of TAM-R MCF7 cells. Consistently, qRT-PCR revealed that TAM-R MCF7 cells expressed increased mRNA levels of stem cell markers including SOX-2, OCT-4, and CD133, compared to those of WT MCF7 cells (P < 0.05). Morphologically, TAM-R MCF7 cells showed a fibroblastic phenotype, but WT MCF7 cells were epithelial-like. After induction of TAM resistance, qRT-PCR indicated that MCF7 cells expressed increased mRNA levels of Snail, vimentin, and N-cadherin and decreased levels of E-cadherin, which are considered as EMT characteristics (P < 0.05).
CONCLUSION: TAM-R MCF7 cells possess CSC characteristics and may be responsible for TAM resistance during breast cancer therapy.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23981606

Source DB:  PubMed          Journal:  Chin Med J (Engl)        ISSN: 0366-6999            Impact factor:   2.628


  16 in total

1.  Tamoxifen induces a pluripotency signature in breast cancer cells and human tumors.

Authors:  George Notas; Vassiliki Pelekanou; Marilena Kampa; Konstantinos Alexakis; Stelios Sfakianakis; Aggelos Laliotis; John Askoxilakis; Eleftheria Tsentelierou; Maria Tzardi; Andreas Tsapis; Elias Castanas
Journal:  Mol Oncol       Date:  2015-06-05       Impact factor: 6.603

Review 2.  Roles and epigenetic regulation of epithelial-mesenchymal transition and its transcription factors in cancer initiation and progression.

Authors:  Jeong-Yeon Lee; Gu Kong
Journal:  Cell Mol Life Sci       Date:  2016-07-26       Impact factor: 9.261

3.  Tumor-Initiating Cells: Emerging Biophysical Methods of Isolation.

Authors:  Efraín A Cermeño; Andrés J García
Journal:  Curr Stem Cell Rep       Date:  2016-02-09

4.  The role of Nanog expression in tamoxifen-resistant breast cancer cells.

Authors:  Khalid Arif; Issam Hussain; Carol Rea; Mohamed El-Sheemy
Journal:  Onco Targets Ther       Date:  2015-06-03       Impact factor: 4.147

5.  FOXA1 expression affects the proliferation activity of luminal breast cancer stem cell populations.

Authors:  Kana Tachi; Akira Shiraishi; Hiroko Bando; Toshiharu Yamashita; Ikki Tsuboi; Toshiki Kato; Hisato Hara; Osamu Ohneda
Journal:  Cancer Sci       Date:  2016-02-19       Impact factor: 6.716

6.  Epithelial-to-mesenchymal transition correlates with gefitinib resistance in NSCLC cells and the liver X receptor ligand GW3965 reverses gefitinib resistance through inhibition of vimentin.

Authors:  Yong Hu; Jialan Zang; Xiaobing Qin; Dali Yan; Haixia Cao; Leilei Zhou; Jie Ni; Shaorong Yu; Jianzhong Wu; Ji-Feng Feng
Journal:  Onco Targets Ther       Date:  2017-04-28       Impact factor: 4.147

7.  HOXA5 confers tamoxifen resistance via the PI3K/AKT signaling pathway in ER-positive breast cancer.

Authors:  Clara Yuri Kim; Yu Cheon Kim; Ji Hoon Oh; Myoung Hee Kim
Journal:  J Cancer       Date:  2021-06-01       Impact factor: 4.207

Review 8.  Expression of stem cell and epithelial-mesenchymal transition markers in circulating tumor cells of breast cancer patients.

Authors:  Natalia Krawczyk; Franziska Meier-Stiegen; Malgorzata Banys; Hans Neubauer; Eugen Ruckhaeberle; Tanja Fehm
Journal:  Biomed Res Int       Date:  2014-05-08       Impact factor: 3.411

Review 9.  Epithelial-Mesenchymal Transition and Breast Cancer.

Authors:  Yanyuan Wu; Marianna Sarkissyan; Jaydutt V Vadgama
Journal:  J Clin Med       Date:  2016-01-26       Impact factor: 4.241

10.  Exostosin 1 regulates cancer cell stemness in doxorubicin-resistant breast cancer cells.

Authors:  Sarala Manandhar; Chang-Gu Kim; Sun-Hee Lee; Soo Hyun Kang; Nikita Basnet; You Mie Lee
Journal:  Oncotarget       Date:  2017-07-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.